Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
Treatment with lopinavir–ritonavir did not add value beyond standard care in severely ill patients hospitalized with novel coronavirus disease (COVID-19). Findings from the open-label, randomized trial appear in the New England Journal of Medicine.
Roughly 200 adults in China hospitalized with COVID-19 and oxygen saturation of 94% or lower were assigned to lopinavir–ritonavir twice daily for 14 days plus standard care, or standard care alone. The primary outcome — time to clinical improvement — did not differ between the groups (median, 16 days). Mortality at 28 days was numerically lower with lopinavir–ritonavir, but the between-groups difference did not reach statistical significance (19% with lopinavir–ritonavir, 25% with standard care alone).
Comment
LINK(S):
NEJM article on lopinavir-ritonavir (Free)
NEJM editorial (Free)
NEJM COVID-19 page (Free)